Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

WAYNE, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS)(the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that effective December 2, 2024, the Compensation Committee of Aclaris’ Board of Directors (the “Committee”) granted nonstatutory stock options to purchase an aggregate of 251,000 shares of its common stock and 73,000 restricted stock units to 4 new employees under the Aclaris Therapeutics, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). In addition, also effective December 2, 2024, the Committee granted Hugh Davis, Ph.D, Aclaris’ new President and Chief Operating Officer, nonstatutory stock options to purchase 375,000 shares of its common stock and 107,000 restricted stock units under the 2024 Inducement Plan. The stock options and restricted stock units were granted as inducements material to the new employees becoming employees of Aclaris in accordance with NASDAQ Listing Rule 5635(c)(4).

Read more at globenewswire.com